But why the sudden interest
Br J Pharmacol (2010) 159:495501
10.1074/jbc.M205854200 [DOI] [PubMed] [Google Scholar] 18.Bao W, Holt LJ, Prince RD, Jones GX, Aravindhan K, Szapacs M, et al
According to FDA prescribing information and clinical trial data, common side effects include nausea (occurring in 1544% of patients depending on dose and indication), vomiting, diarrhea, abdominal pain, and constipation
Notably, patients with a BMI 35 kg/m 2 experienced greater benefits than those with lower BMI, potentially underscoring the benefit derived from targeting obesity-related metabolic drivers of heart failure rather than modulation of myocardial loading or neurohormonal mediation [118, 121]
Semaglutide at the 2.4 mg dose is FDA-approved for chronic weight management in adults with obesity or overweight with a weight-related condition, regardless of diabetes status